RxDoctor Payments DataLook up a doctor →

Bradley Rodgers, MD

Obstetrics · Kearney, NENPI 1154405926

Payments from drug & device makers

$18,516in general payments, 2019–2025

Across 548 payments — averaging $33.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optinose US, Inc.$5K
  • Cue Health Inc.$4K
  • AbbVie$2K
  • Medtronic$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$769
  • Novo Nordisk$554
  • plus $5K from 52 others

What the payments were for

  • Consulting fees$1,1618%
  • Speaking & faculty fees$3,24022%
  • Travel & lodging$1,83512%
  • Food & beverage$8,74758%
  • Education$330%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Optinose US, Inc.15$5,308
Cue Health Inc.1$3,500
AbbVie(2 entities)224$2,033
Medtronic8$1,488
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)17$769
Novo Nordisk32$554
AstraZeneca14$474
Lilly USA, LLC33$364
Pfizer27$346
Amgen(2 entities)26$343
Johnson & Johnson17$310
Otsuka America Pharmaceutical, Inc.14$257
Bayer7$171
Next Science LLC2$161
Upsher-smith Laboratories LLC11$154
Sanofi3$151
Musculoskeletal Transplant Foundation Inc.1$137
Astellas Pharma US Inc6$129
Organogenesis Inc.4$124
Xeris Pharmaceuticals, Inc.6$119
Boston Scientific1$93
Takeda Pharmaceuticals U.S.A., Inc.5$85
Inari Medical, Inc.1$80
Eisai Inc.3$75
Biocryst US Sales Co., LLC1$73
Biohaven Pharmaceutical Holding Company Ltd.2$73
Kerecis Limited2$71
Abbott3$64
Genentech USA, Inc.5$61
Myriad Women's Health, Inc.1$61
Lundbeck LLC3$57
Novartis4$57
Idorsia Pharmaceuticals US Inc4$56
GSK4$52
Dexcom, Inc.3$49
Sanofi-aventis U.S. LLC3$48
Pulmonx Corporation2$44
Averitas Pharma Inc.2$40
Boehringer Ingelheim3$40
Smith+Nephew2$38
Merck3$37
Arbor Pharmaceuticals, Inc.3$36
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$33
Axsome Therapeutics, Inc.2$32
Biohaven Pharmaceuticals, Inc.2$32
Conetic Solutions, Inc.2$30
Protega Pharmaceutials Inc1$27
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$20
KCI USA, Inc.1$19
Forte Bio-pharma LLC1$18
Insulet Corporation1$18
Aimmune Therapeutics, Inc.1$17
Ironwood Pharmaceuticals, Inc1$17
Paratek Pharmaceuticals, Inc.1$15
Ironshore Pharmaceuticals Inc.1$15
Sanofi Pasteur Inc.1$15
Incyte Corporation1$14
Kowa Pharmaceuticals America, Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few obstetrics providers in Nebraskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$505,767
Medicare patients
583
Services billed
6,496

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban163$102,360
OzempicSemaglutide86$94,464
JardianceEmpagliflozin115$92,058
XareltoRivaroxaban140$69,088
Trelegy ElliptaFluticasone/Umeclidin/Vilanter87$65,100
FarxigaDapagliflozin Propanediol66$58,425
Tresiba Flextouch U-200Insulin Degludec26$36,470
RybelsusSemaglutide31$34,799
Xtampza ErOxycodone Myristate28$27,221
TradjentaLinagliptin29$21,757
JanuviaSitagliptin Phosphate23$20,381
MyrbetriqMirabegron25$17,934
JanumetSitagliptin Phos/Metformin Hcl31$17,368
MounjaroTirzepatide16$16,742
LinzessLinaclotide16$16,088

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$554$129,263117 claims
Boehringer IngelheimJardiance, Tradjenta$40$113,815144 claims
PfizerEliquis$346$102,360163 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$52$95,503151 claims
Johnson & JohnsonXarelto$310$69,088140 claims
AstraZenecaFarxiga, Breztri Aerosphere$474$67,32880 claims
MerckJanuvia, Janumet, Janumet Xr$37$43,40165 claims
Astellas Pharma US IncMyrbetriq, Veozah$129$29,63245 claims
AbbVieLinzess, Creon$2,033$23,06136 claims
Lilly USA, LLCMounjaro$364$16,74216 claims
Arbor Pharmaceuticals, Inc.Horizant$36$7,68415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few obstetrics providers in Nebraskaon file to place this against a meaningful peer group, so we don't.

Other obstetrics in Kearney

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →